Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02588651
Title A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Deepa Jagadeesh

mature T-cell and NK-cell lymphoma

adult T-cell leukemia/lymphoma


Brentuximab vedotin

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.